Jaguar Health, Inc. (JAGX)
| Market Cap | 3.71M |
| Revenue (ttm) | 11.69M |
| Net Income (ttm) | -38.49M |
| Shares Out | 674.04K |
| EPS (ttm) | -130.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,354 |
| Open | 5.50 |
| Previous Close | 5.61 |
| Day's Range | 5.47 - 5.50 |
| 52-Week Range | 4.02 - 540.00 |
| Beta | 1.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2025 |
About JAGX
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company’s products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief o... [Read more]
Financial Performance
In 2024, Jaguar Health's revenue was $11.69 million, an increase of 19.75% compared to the previous year's $9.76 million. Losses were -$38.49 million, -6.80% less than in 2023.
Financial StatementsNews
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and mi...
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 20...
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product
Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most signifi...
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 res...
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement...
Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Conference Call Participants Operator Greetings, and welcome to the Jaguar Health Inv...
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus ...
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA In dogs undergoing chemotherapy, as is the case with pe...
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poste...
Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts
Click here to register for Jaguar's March 27 virtual presentation at the Emerging Growth Conference Click here to register for Jaguar's March 31 investor webcast Company plans to file its annual repor...
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that Jaguar's president and chief executive officer Lisa Conte, th...
Jaguar Health, Inc. Announces Reverse Stock Split
Reverse split approved at March 2025 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on March 24, 2025 SAN FRANCISCO, CA / ACCESS Newswire...
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis...
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value
Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis...
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indicat...
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-rela...
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
SAN FRANCISCO, CA / ACCESS Newswire / February 13, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Tuesday...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
Trial taking place at Sheikh Khalifa Medical City , a flagship United Arab Emirates hospital and largest teaching medical center in Abu Dhabi Crofelemer, Jaguar's novel plant-based prescription drug, ...
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been rep...
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that the first patient has been dosed in the independent investigator-init...
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase
SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside c...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications su...
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications The import was conducted in collaboration with the government of P...
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short bow...